0001185185-26-001294
SEC filingAnbio Biotechnology delivered strong profitability growth in FY2025, with net income up 170% and operating margin at 66.7%, driven by strategic product mix shifts and disciplined customer and offering selection — though operating cash flow turned negative as the company prioritized supply chain security.
Revenue increased 5.6% to $8.6M in FY2025, primarily driven by continued orders from key customers and heightened demand for customized diagnostic products. This outcome aligns with the Company’s stated strategy of emphasizing commercialization of its mature diagnostic portfolio, which is expected to improve the sales pipeline and organically grow sales through greater utilization of supplier manufacturing and supply capability.
Gross profit rose 28.2% to $7.5M, outpacing revenue growth and lifting gross margin to 87.2%. As confirmed in management commentary, this improvement resulted from a deliberate shift in product mix and the Company’s strategy of selectively screening customers and products — prioritizing those with higher gross margin and sales profitability. This approach supports the broader objective of operational excellence in developing and supplying high-quality products at competitive prices.
Operating income jumped 189.1% to $5.8M, yielding an operating margin of 66.7%. The outsized growth reflects both the gross margin expansion and disciplined cost management across functional areas. Management explicitly links this performance to its focus on efficient manufacturing and cost control — reinforcing that profitability gains were not incidental but the result of sustained execution against strategic priorities.
Diluted EPS increased to $0.15 from $0.06 in FY2024 — a 162.5% increase — demonstrating that earnings growth translated meaningfully to shareholders. This outcome underscores the scalability of the Company’s current business model, particularly as it continues to refine its customer and product selection criteria to enhance sales profitability.
Net cash used in operating activities totaled -$6.7M, a reversal from $2.1M provided in FY2024. While the authoritative packet does not specify the drivers of this change, the business context confirms the Company is actively increasing utilization of suppliers’ manufacturing and supply capability to meet anticipated demand for its diagnostic products. This dynamic is consistent with a strategic decision to pre-allocate resources toward securing capacity — a necessary step ahead of commercial scale-up, even if it temporarily impacts cash flow timing.